Info@NeuroCareUSA.com 918-359-3549

Long-Term Effects of Ozone Treatment in Patients with Persistent Numbness and Tingling Secondary to Chemotherapy-Induced Peripheral Neuropathy. A Retrospective Study

  • Home
  • Blogs
  • Long-Term Effects of Ozone Treatment in Patients with Persistent Numbness and Tingling Secondary to Chemotherapy-Induced Peripheral Neuropathy. A Retrospective Study

Long-Term Effects of Ozone Treatment in Patients with Persistent Numbness and Tingling Secondary to Chemotherapy-Induced Peripheral Neuropathy. A Retrospective Study

Integr Cancer Ther
2025 Jan 11;24:15347354241307038. doi: 10.1177/15347354241307038
Author
Bernardino Clavo , Delvys Rodríguez-Abreu , Saray Galván-Ruiz , Mario Federico , Angeles Cánovas-Molina , Yolanda Ramallo-Fariña , Carla Antonilli , Gretel Benítez , Himar Fabelo , Carla García-Lourve , Damián González-Beltrán , Ignacio J Jorge , Francisco Rodríguez-Esparragón , Gustavo M Callico

1Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain

2Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Las Palmas de Gran Canaria/Tenerife, Spain

3University of Las Palmas de Gran Canaria (ULPGC), Las Palmas de Gran Canaria, Spain

4Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias de la Universidad de La Laguna, La Laguna, Tenerife, Spain

5CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain

6Spanish Group of Clinical Research in Radiation Oncology (GICOR), Madrid, Spain

7Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Las Palmas de Gran Canaria, Spain

8Network for Research on Chronicity, Primary Care, and Health Promotion (RICAPPS), Barcelona, Spain

9Servicio de Evaluación y Planificación del Servicio Canario de Salud (SESCS), Santa Cruz de Tenerife, Spain

Received 2024 Sep 4; Revised 2024 Oct 11; Accepted 2024 Nov 28; Collection date 2025.

Abstract
Background
Numbness and tingling secondary to chemotherapy-induced peripheral neuropathy (CIPN) are frequent side effects that limit chemotherapy treatment and quality of life. Successful treatments for CIPN are limited. This preliminary report shows the potential long-term effects of ozone treatment in the management of persistent numbness and tingling secondary to CIPN.
Methods
Ozone treatment was administered by rectal insufflation in 15 patients (female/male: 8/7, age: 66 years old) suffering from persistent numbness and tingling secondary to grade-2 or grade-3 CIPN. Planned ozone treatment consisted of 40 sessions over 4 months. The initial concentration of 10 μg/mL was progressively increased to 30 μg/mL. The initial gas volume of 180 mL/session was progressively increased to 300 mL/session if tolerated. Before and after ozone treatment, and at 3- and 6- months after the end of treatment, they were assessed (i) the grade of CIPN-toxicity, and (ii) the self-reported decrease in numbness and tingling.
Results
After ozone treatment, 47% of patients experienced a decrease in the grade of CIPN-toxicity (P = .016), and 67% of patients reported a decrease in numbness and tingling ≥50% (P = .002). These effects were maintained at 3- and 6- months after the end of O3T.
Conclusion
In this retrospective report, patients with persistent numbness and tingling secondary to CIPN showed clinically relevant and long-term improvements after ozone treatment. The magnitude and duration of the observed effects merit further research and support our ongoing clinical trials.
Keywords:
numbness and tingling, paresthesias, chemotherapy-induced peripheral neuropathy, grade of toxicity, side effects, cancer survivors, ozone treatment, oxidative stress modulation, Nrf2